The Geneva Foundation

1. Intercept Pharmaceuticals, Inc. $1,929,965 239 payments
2. Intercept Pharma Europe Ltd. $295,230 22 payments
3. Pfizer Inc. $164,015 44 payments
4. Celgene Corporation $146,361 28 payments
5. E.R. Squibb & Sons, L.L.C. $119,530 21 payments
6. Takeda Pharmaceuticals U.S.A., Inc. $110,227 14 payments
7. AstraZeneca Pharmaceuticals LP $108,391 21 payments
8. Janssen Research & Development, LLC $86,683 12 payments
9. Madrigal Pharmaceuticals $80,940 58 payments
10. Mitsubishi Tanabe Pharma America, Inc. $65,432 16 payments

1. Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) $656,436 73 payments
2. 1011866 $630,279 45 payments
3. Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) $430,871 34 payments
4. 1009742 $274,872 60 payments
5. Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (REVERSE) $142,622 24 payments
6. Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (REVERSE) $90,116 25 payments
7. A Phase 3 Multinational Doubleblind Randomized Placebocontrolled Study of Mgl3196 Resmetirom in Patients With Nonalcoholic Steatohepatitis Nash and Fibrosis to Resolve Nash and Reduce Progression to Cirrhosis Andor Hepatic Decompensation $80,940 58 payments
8. A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma who have Received 1 to 3 Prior Lines of Ther $66,098 8 payments
9. A Phase 2A, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of MT-3921 in Subjects With Acute Traumatic Cervical Spinal Cord Injury $63,079 13 payments
10. To assess the efficacy and safety of AZD9291 versus Placebo in patients with Epidermal Growth Factor Receptor Mutation Positive stage IB IIIA non small cell lung carcinoma following complete tumour resection with or without adjuvant chemotherapy $57,815 10 payments

1. Other $43,289 4 payments
2. Patient care $18,310 5 payments
3. Professional salary support $11,740 4 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.